On February 12, 2019 VBL Therapeutics (Nasdaq: VBLT), reported that the Company will present new data on the potential of its VB-600 platform targeting MOSPD2 for inflammatory and oncology indications, at the Keystone Symposia on Myeloid Cells, to be held February 24—28, 2019 at the Eldorado Hotel & Spa in Santa Fe, New Mexico (Press release, VBL Therapeutics, FEB 19, 2019, View Source [SID1234533475]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation Details:
Title: MOSPD2: Key Regulator of Myeloid Cell Migration and a Novel Target for Treatment of Inflammatory Diseases
Presenter: Itzhak Mendel, PhD
Date: Tuesday, February 26, 2019
Time: 8:00 – 11:00 AM MST
Session: Myeloid Cells in Metabolic and Inflammatory Diseases
Location: Eldorado Grand Ballroom

Poster Presentation Details:
Abstract: MOSPD2: Key Regulator of Myeloid Cell Migration and a Novel Target for Treatment of Inflammatory Diseases
Session title: Poster Session 2
Date: Tuesday, February 26, 2019
Time: 7:30 – 10:00 PM MST
Poster #: 2028
For more information on the Keystone Symposium on Myeloid Cells, including a detailed program, refer to View Source;meetingid=1553

About VBL’s VB-600 Platform

VBL is conducting two parallel drug development programs that are exploring the potential of MOSPD2, a protein that VBL has identified as a key regulator of cell motility, as a therapeutic target for inflammatory diseases and cancer. Our VB-600 platform comprises classical anti-MOSPD2 monoclonal antibodies for inflammatory indications, as well as bi-specific antibody candidates for oncology.